Reata Pharmaceuticals Business Operations and Clinical Development Updates
Reata Pharmaceuticals (RETA) – a clinical-stage biopharmaceutical company announced financial results for the quarter ended September 30, 2021, and provided an update on the Company’s business operations and clinical development programs.
Recent Highlights
Bardoxolone in Patients with Chronic Kidney Disease (CKD) Caused by Alport Syndrome

The New Drug Application (NDA